mTOR Inhibitor Pharmacology
How sirolimus and everolimus block mTOR-driven cell cycle progression, their role in transplantation, and dual immunosuppressive-antiproliferative activity.
## Mechanism of Action
**Sirolimus** (rapamycin) and **everolimus** bind FKBP12 -- the same immunophilin that tacrolimus binds. However, the sirolimus-FKBP12 complex inhibits **mTOR (mechanistic target of rapamycin)** rather than calcineurin. mTOR is a serine/threonine kinase that integrates nutrient and growth factor signals to drive cell cycle progression from G1 to S phase.
By blocking mTOR complex 1 (mTORC1), these agents inhibit:
- IL-2-driven T-cell proliferation
- Antibody production by B cells
- Smooth muscle and endothelial cell proliferation
- HIF-1alpha-mediated VEGF expression (anti-angiogenic)
This antiproliferative profile distinguishes mTOR inhibitors from calcineurin inhibitors, which primarily block T-cell activation signals rather than proliferation.
## Clinical Applications
In **transplantation**, mTOR inhibitors serve as CNI-sparing agents. Converting from tacrolimus to sirolimus/everolimus preserves graft function in patients developing CNI nephrotoxicity. They are also used as primary immunosuppression in combination with reduced-dose CNIs.
Everolimus-eluting coronary stents exploit the antiproliferative effect to prevent restenosis. In oncology, everolimus and temsirolimus treat renal cell carcinoma, breast cancer (HR+/HER2-), and neuroendocrine tumors by blocking mTOR-dependent tumor growth.
Sirolimus is also approved for lymphangioleiomyomatosis (LAM), a rare lung disease driven by mTOR pathway hyperactivation due to TSC gene mutations.
## Pharmacokinetics
Both agents have long half-lives: sirolimus ~62 hours, everolimus ~30 hours. They are CYP3A4 substrates with the same drug interaction profile as CNIs. Therapeutic drug monitoring targets sirolimus trough levels at 4-12 ng/mL (transplant) and everolimus at 3-8 ng/mL.
Oral bioavailability is approximately 15% for sirolimus and 16% for everolimus. High-fat meals increase sirolimus Cmax by 35%, requiring consistent administration relative to food.
## Adverse Effects
**Dyslipidemia** is the hallmark adverse effect -- hypercholesterolemia and hypertriglyceridemia occur in 40-75% of patients, often requiring statin therapy. Other notable effects include:
- **Impaired wound healing**: Antiproliferative activity delays surgical wound closure
- **Myelosuppression**: Thrombocytopenia, leukopenia, and anemia
- **Proteinuria**: Particularly when combined with CNIs
- **Pneumonitis**: Drug-induced interstitial lung disease (2-10%)
- **Mouth ulcers**: Aphthous-type stomatitis, especially with everolimus
## Key Takeaways
- mTOR inhibitors block cytokine-driven proliferation, complementing calcineurin inhibitor activity
- Antiproliferative effects extend utility to oncology and drug-eluting stents
- Long half-lives and CYP3A4 metabolism necessitate TDM and interaction awareness
- Dyslipidemia and impaired wound healing are characteristic class effects